CRC_CAIN457A2326

CLARITY A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess longterm safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis

Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.

Key Inclusion Criteria:

Chronic plaque-type psoriasis present for at least 6 months and diagnosed before randomization

Moderate to severe plaque psoriasis

Candidate for systemic therapy, defined as having psoriasis inadequately controlled by:
Topical treatment (including topical corticosteroids) and/or
Phototherapy and/or
Previous systemic therapy
Phase IIIb
NCT02826603
All Other
Dermatology
David Smith, M.D.
Novartis
Dean Rocco
  • Everett Clinic